Research Progress of Antifibrotic Drugs in the Treatment of Pulmonary Fibrosis after Novel Coronavirus Pneumonia

截至2023年5月5日，世界卫生组织已宣布由严重急性呼吸系统综合征冠状病毒2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)感染引起的新型冠状病毒肺炎(coronavirus disease-19, COVID-19)不再构成国际关注的突发公共卫生事件，但至今为止，人类对于日趋出现的新冠肺炎呼吸道后遗症的诊治仍处于探索阶段。其中，可能会发生造成永久性肺损伤的肺纤维化由于其在重症COVID-19幸存者中的高发生率引发关注。肺纤维化(pulmonary fibrosis, PF)是一种慢性进行性肺部疾病，通常会造成肺部的持续性结构破坏和呼吸衰竭。本文结合国内外最新文献，对抗纤维化药物治疗新冠肺炎导致的PF进行综述，旨在更好地指导相关治疗。As of May 5, 2023, the World Health Organization has announced that coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection will no longer constitute a public health emergency of international concern, but so far, the diagnosis and treatment of the respiratory sequelae of emerging COVID-19 are still in the exploratory stage. Among them, pulmonary fibrosis, which may cause permanent lung injury, has attracted attention due to its high incidence in survivors of severe COVID-19. Pulmonary Fibrosis (PF) is a chronic progressive lung disease, which usually causes persistent structural destruction of the lungs and respiratory failure. This article reviews the latest literature at home and abroad on the treatment of PF caused by COVID-19 with antifibrotic drugs, in order to better guide the related treatment.